<DOC>
	<DOCNO>NCT02621047</DOCNO>
	<brief_summary>This multicenter , non-randomized , single-dose , open-label study conduct male surgically sterile post-menopausal female participant stable chronic hepatic impairment healthy participant match age , gender , body weight assess effect hepatic impairment pharmacokinetics alectinib .</brief_summary>
	<brief_title>Effect Hepatic Impairment Pharmacokinetics Alectinib</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All Participants Body mass index 18 35 kilogram per square meter ( kg/m^2 ) inclusive weight great ( &gt; ) 50 kilogram ( kg ) Female participant must surgically sterile postmenopausal Male participant partner childbearing potential must willing use 2 effective method contraception , one must barrier method Participants Hepatic Impairment Documented chronic stable liver disease ( ChildPugh Class A , B C ) All Participants Pregnant lactate woman , male female partner pregnant lactating , woman child bear potential Positive test drug abuse alcohol Participation investigational drug device study within 45 day 5 halflives ( whichever time period longer ) 6 month biologic therapy prior study drug administration History hypersensitivity additives alectinib formulation Participants judicial supervision , guardianship , curatorship History severe drugrelated allergic reaction druginduced hepatotoxicity Healthy Participants Use medication ( prescription overthecounter ) , within 2 week 5 halflives ( whichever longer ) prior study drug administration Use herbal supplement metabolic inducer within 4 week , 5 halflives ( whichever longer ) prior study drug administration Participants Hepatic Impairment Positive screen test human immunodeficiency virus ( HIV ) History liver transplantation Hepatocellular carcinoma acute liver disease Severe ascites screen admission clinic Recent history ( past 2 year ) current severe hepatic encephalopathy ( Grade 3 high ) Any evidence progressive liver disease within last 4 week Presence surgically create transjugular intrahepatic portal systemic shunt</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Alectinib</keyword>
	<keyword>Hepatic impairment</keyword>
</DOC>